EUCTR2015-001602-33-GB进行中（未招募）1 期
A single arm, phase II open label trial to investigate the efficacy and safety of intra-dermal injection of etanercept for remission induction in discoid lupus erythematosus - TARGET-DLE version 2.0
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •(i) Adults aged 18-65 years old.
- •(ii) Have at least one active DLE lesion, either diagnosed by skin biopsy or confirmation by Consultant Dermatologist/Rheumatologist.
- •(iii) Patients with DLE only and SLE patients with DLE are included.
- •(iv) Have refractory disease to an anti-malarial at 3 months as assessed by the Dermatologist/Rheumatologist.
- •(v) Patients receiving anti-malarials must have been receiving them for at least 3 months prior to Screening, with a stable dose regimen for at least 28 days (±1 day) prior to Baseline (the first study drug administration)
- •(vi) Ability to provide an informed consent.
- •(vii) All male and female patients biologically capable of having children must agree to use a reliable method of contraception for the duration of the study and for a period of 3 weeks after their final dose of study drug. Acceptable methods of contraception are surgical sterilisation, oral, implantable or injectable hormonal methods, intrauterine devices or barrier contraceptives.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 25
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •(i) Any prior treatment with TNF-blockade therapies.
- •(ii) Intramuscular or intra-dermal corticosteroid within 28 days of the Screening visit.
- •(iii) Oral steroid of greater than 10mg prednisolone daily, or change in oral steroid dose within 28 days prior to the Baseline Visit.
- •(iv) A change in the dose of other immunosuppressant including methotrexate, azathioprine and mycophenolate mofetil within 28 days (±1 day) prior to Baseline Visit.
- •(v) Concomitant therapies with any alkylating agents (e.g. cyclophosphamide, chlorambucil), other immunosuppressant including sulfasalazine and leflunomide, other biological agent particularly anakinra and abatacept and other experimental drug. If patients are on any of these, they need to be off therapies for at least 28 days prior to Baseline Visit to allow for washout.
- •(vi) Evidence of an immunosuppressive state, including an active HIV infection, agammaglobulinaemia, T-cell deficiencies or Human T cell Lymphotrophic Virus Type 1 (HTLV-1).
- •(vii) Chronic active infection such as hepatitis B or hepatitis C and tuberculosis. Patients with latent tuberculosis may be included if treated with chemoprophylaxis for at least 2 months before starting the study and to continue chemoprophylaxis for a total of 6 months
- •(viii) History of cancer within the last 5 years except for squamous or basal cell skin carcinoma that has been completely excised and treated cervical carcinoma in situ.
- •(ix) Demyelinating diseases.
- •(x) Moderate to severe heart failure based on New York Heart Association (NYHA) functional class III and IV.
- •(xi) Pregnancy.
- •(xii) Breastfeeding.
- •(xiii) Planned surgery within the study period which is expected to require omission of study medication of 28 days or more.
- •(xiv) Receipt of live attenuated vaccine within 28 days prior to the Baseline Visit.
研究者
相似试验
进行中（未招募）
不适用
Sym004 in head and neck cancer patients failing anti-EGFR based therapyRecurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN)MedDRA version: 14.1Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-000902-24-DESymphogen A/S25
进行中（未招募）
1 期
Sym004 in head and neck cancer patients failing anti-EGFR based therapyRecurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN)EUCTR2011-000902-24-BESymphogen A/S25
招募中
不适用
Open-Label, Single arm, Phase II trial to evaluate efficacy and safety of Nivolumab as maintenance therapy following Platinum-based chemotherapy in non-small cell lung cancer patients after tyrosine kinase Inhibitor therapyNeoplasmsKCT0004541Asan Medical Center26
招募中
2 期
A clinical trial to study the effects and the antiviral activity of TMC278 in HIV-1 infected adolescent patients aged 12 to 18 yearsCTRI/2011/06/001796Johnson and johnson Ltd35
进行中（未招募）
1 期
A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Efficacy of rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and children aged greater than or equal to 6 yearsEUCTR2008-001696-30-Outside-EU/EEAJanssen Sciences Ireland UC